FDA: AstraZeneca's diabetes drug Onglyza may increase death rate

April 10, 2015 12:53 PM

17 0

(Reuters) - AstraZeneca Plc's diabetes drug Onglyza may be associated with an increased rate of death, according to a preliminary review of data by the U.S. Food and Drug Administration.

The FDA's report, posted on the agency's website on Friday, comes ahead of an April 14 meeting of an FDA advisory panel to discuss the drug's safety.

Read more

To category page